VENATORX PHARMACEUTICALS, INC.

Basic Information

30 Spring Mill Drive
Malvern, PA, 19355-1200

Company Profile

n/a

Additional Details

Field Value
DUNS: 962754037
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 18


  1. Broad-spectrum, orally-bioavailable beta-lactamase inhibitors

    Amount: $599,200.00

    DESCRIPTION (provided by applicant): Broad-spectrum, orally bioavailable -lactam antibiotics play a critical role in the management of human infectious diseases, both in the hospital and community se ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Phase II SBIR: Responding to NDM-1- Advancement of a new MBL inhibitor to IND

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. While carbapenems are among the most prescribed antibiotics for infections caused b ...

    SBIR Phase II 2013 Department of Health and Human Services
  3. Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Multi-drug resistance in Enterobacteriaceae is regarded as a healthcare crisis. This crisis has been further amplified by the recent emergence of the NDM-1 su ...

    SBIR Phase II 2013 Department of Health and Human Services
  4. Novel Compounds Targeting Bacterial PBPs

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): This Phase I SBIR Application centers on a new class of non-??-lactam antibacterial agents that target the same biological target as the ?-lactam class of antibiot ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Novel Metallo-beta-lactamase Inhibitors

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as ...

    SBIR Phase I 2011 Department of Health and Human Services
  6. Preserving beta-lactam utility against pathogens producing all classes of beta-la

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): This Phase I SBIR Grant focuses on advancement of a new class of inhibitors of serine-based b-lactamases (Ambler classes A, C and D), for combination with the only ...

    SBIR Phase I 2011 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government